Loading…
← CockpitCompetitor Analysis › ZJYL Jin Medical International Ltd. Class AOpen in the cockpit ↗

Jin Medical International Ltd. Class AZJYLCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties
Momentum leader 96
Mkt cap
$532M
US dollars, full cap
Free float
94%
of shares outstanding
$/day
$646,586
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-17.9 pp
WACC 19.5%
Hurdle
n/a
no reverse DCF
Close · USD$3.36
1D-0.4%
1W-31.6%
1M+65.5%
3M+10.9%
6M+47.4%
YTD-23.6%
1Y-34.3%
ATR %12.8%
Beta1.14
52w lowhigh40.8% off high

What Jin Medical International does

Employees: 295

Jin Medical International at a glance

Size Jin Medical International (ZJYL) is a United States Health Care company (Medical Specialties) with a market value of $532M, the 2632nd largest of 3,085 United States companies the cockpit tracks. Shares closed at $3.36 on 18 Nov 2026.

Performance Over six months the shares gained 47.4%, against -23.4% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd highest of 21 in its peer set.

Growth Revenue fell 13.6% over the last twelve months (peer median +6.1%); the operating margin is 2.1% (peer median 2.5%).

Valuation It trades at 26.5× enterprise value to sales against a peer median of 3.0× (2nd most expensive of 19).

Capital Return on invested capital runs 17.9 points below its cost of capital (19.5% WACC).

Relative performance

10015020021 May 202621 Aug 202618 Nov 2026ZJYL 147Peer median 78
Six months, rebased to 100: Jin Medical International against the median of its 20 peers (local-currency closes).

Jin Medical International financials

Reported figures in USD; fiscal year ends 2025-09-30. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$19.7M$20.7M$23.5M$19.8M$19.2M
Revenue growth—-12%+19%+3%—
Gross profit$6.04M$6.04M$9.50M$6.78M$6.20M
EBITDA$704,460$932,860$3.97M$3.09M$2.49M
Net income$1.17M$1.19M$3.68M$2.88M$2.71M
Free cash flow-$6.96M-$3.73M-$1.35M$2.99M$1.54M
Capital expenditure$6.37M$6.63M$1.12M$113,937$40,166
Total debtn/a$18.5M$11.4M$4.11M$0

Quarterly statements and history in the cockpit →

Jin Medical International competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%0%+25%+50%MYGNRCEL605369300439NNNN3008693006397979AVR603122301235688580MEDXPACB300952603520ZJYL6-month return →1-month return →
Up and to the right = strong over both horizons. Jin Medical International is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%0×50×100×MYGNRCEL6053693004393008697979AVR688075603122301235688298PACBZJYLRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Jin Medical International is the large dot.

Jin Medical International competitors and peer comparison

How Jin Medical International compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Jin Medical International against its 20 peers (data as of 18 Nov 2026)
MeasureZJYLPeer medianRank in peer set
1-month return+65.5%-6.7%highest of 21
6-month return+47.4%-23.4%3rd highest of 21
Distance from 52-week high-40.8%-44.6%9th highest of 21
Revenue growth (TTM)-13.6%+6.1%2nd lowest of 21
Operating margin2.1%2.5%10th lowest of 21
EV / Sales26.5×3.0×2nd most expensive of 19
ROIC minus cost of capital-17.9 pp-2.2 pp3rd lowest of 18
Net debt / EBITDA-13.5×-1.7×least indebted of 4

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Jin Medical International ZJYLUnited States$532M+47%-14%2%26.5×n/an/a
Myriad Genetics MYGNUnited States$530M+45%-3%-13%0.8×n/an/a
AVITA Medical RCELUnited States$529M+290%+17%-34%6.7×n/an/a
Zhejiang Gongdong Medical Technology 605369.SSChina$542M-21%+6%9%2.6×10.2%+6.5%
MedicalSystem Biotechnology 300439.SZChina$518M-9%+14%2%1.5×6.0%-7.7%
Anbio Biotechnology NNNNUnited States$518M-89%+10%67%n/an/an/a
Contec Medical Systems 300869.SZChina$547M-26%-2%-16%5.5×15.0%-19.8%
Guangdong Hybribio Biotech 300639.SZChina$511M-18%-7%4%3.9×0.4%-13.2%
Shofu 7979.TJapan$510M+32%+9%14%1.6×n/an/a
Anteris Technologies Global AVRUnited States$508M-40%+9%-4,880%125.0×n/an/a
Assure Tech (Hangzhou) 688075.SSChina$508M-27%-9%-8%5.4×30.8%-18.6%
Cowealth Medical China 603122.SSChina$562M-34%-18%-5%5.9×n/an/a
Wuhan Huakang Century Clean Technology 301235.SZChina$563M-57%+28%7%1.6×n/an/a
Zhejiang Orient Gene Biotech 688298.SSChina$500M-27%+18%-60%1.6×n/an/a
Nanjing Vishee Medical Technology 688580.SSChina$499M-43%+7%24%5.3×20.1%+4.2%
medmix MEDX.SWSwitzerland$494M+11%-7%6%1.4×4.5%+5.0%
Pacific Biosciences of California PACBUnited States$573M+54%+4%-98%6.7×n/an/a
Jiangsu Hanvo Safety Product 300952.SZChina$575M-38%+6%8%3.3×n/an/a
Zhejiang Starry Pharmaceutical 603520.SSChina$491M-44%+9%3%2.2×n/an/a
Wuhan Easy Diagnosis Biomedicine 002932.SZChina$485M-14%-9%-51%n/an/an/a
Hangzhou Alltest Biotech 688606.SSChina$484M-20%0%13%1.3×-6.5%-4.3%

Questions

Which companies are Jin Medical International's closest peers?
The cockpit's peer set: Myriad Genetics (MYGN), AVITA Medical (RCEL), Zhejiang Gongdong Medical Technology (605369.SS), MedicalSystem Biotechnology (300439.SZ), Anbio Biotechnology (NNNN), Contec Medical Systems (300869.SZ), Guangdong Hybribio Biotech (300639.SZ), Shofu (7979.T).
Is Jin Medical International expensive compared with its peers?
On ev / sales it trades at 26.5× against a peer median of 3.0×, 2nd most expensive of 19 in its peer set.
How has Jin Medical International stock performed?
Over six months to 18 Nov 2026 the shares returned +47.4% against -23.4% for the median peer; over one year -34.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.